For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Transmedics Group Inc (NASDAQ: TMDX) closed at $124.98 in the last session, up 0.42% from day before closing price of $124.46. In other words, the price has increased by $0.42 from its previous closing price. On the day, 0.64 million shares were traded. TMDX stock price reached its highest trading level at $125.57 during the session, while it also had its lowest trading level at $120.75.
Ratios:
We take a closer look at TMDX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 35.40. For the most recent quarter (mrq), Quick Ratio is recorded 7.13 and its Current Ratio is at 7.69. In the meantime, Its Debt-to-Equity ratio is 1.46 whereas as Long-Term Debt/Eq ratio is at 1.44.
On October 13, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $145.
On September 16, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $155.Evercore ISI initiated its Outperform rating on September 16, 2025, with a $155 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 29 ’25 when Basile Edward M sold 4,142 shares for $130.45 per share. The transaction valued at 540,324 led to the insider holds 2,866 shares of the business.
EDWARD BASILE bought 4,142 shares of TMDX for $540,324 on Oct 29 ’25. On Aug 06 ’25, another insider, Hassanein Waleed H, who serves as the President & CEO of the company, bought 8,400 shares for $118.68 each. As a result, the insider paid 996,912 and bolstered with 477,759 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 4271107072 and an Enterprise Value of 4324282368. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 50.48, and their Forward P/E ratio for the next fiscal year is 43.66. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.95. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.54 while its Price-to-Book (P/B) ratio in mrq is 12.01. Its current Enterprise Value per Revenue stands at 7.635 whereas that against EBITDA is 35.871.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.07, which has changed by 0.4475459 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $145.50, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 6.17%, while the 200-Day Moving Average is calculated to be 19.97%.
Shares Statistics:
According to the various share statistics, TMDX traded on average about 996.96K shares per day over the past 3-months and 1324740 shares per day over the past 10 days. A total of 34.14M shares are outstanding, with a floating share count of 33.03M. Insiders hold about 3.36% of the company’s shares, while institutions hold 108.49% stake in the company. Shares short for TMDX as of 1760486400 were 7971237 with a Short Ratio of 8.00, compared to 1757894400 on 8394299. Therefore, it implies a Short% of Shares Outstanding of 7971237 and a Short% of Float of 40.060002.
Earnings Estimates
. The current rating of Transmedics Group Inc (TMDX) is the result of assessments by 7.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.76, with high estimates of $0.79 and low estimates of $0.71.
Analysts are recommending an EPS of between $2.82 and $2.38 for the fiscal current year, implying an average EPS of $2.59. EPS for the following year is $3.02, with 8.0 analysts recommending between $3.52 and $2.56.
Revenue Estimates
According to 10 analysts,. The current quarter’s revenue is expected to be $156.34M. It ranges from a high estimate of $160.1M to a low estimate of $155M. As of. The current estimate, Transmedics Group Inc’s year-ago sales were $121.62MFor the next quarter, 10 analysts are estimating revenue of $170.61M. There is a high estimate of $181.5M for the next quarter, whereas the lowest estimate is $163.4M.
A total of 12 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $604.8M, while the lowest revenue estimate was $599M, resulting in an average revenue estimate of $601M. In the same quarter a year ago, actual revenue was $441.54MBased on 12 analysts’ estimates, the company’s revenue will be $724.96M in the next fiscal year. The high estimate is $753.9M and the low estimate is $686.8M.
